Sign in
Taking peoplePhase 3

Metformin compared with placebo for muscle function in myotonic dystrophy type 1

Tests metformin against placebo for muscle function in adults with myotonic dystrophy type 1.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France16 sites in 1 countryChoose a country to see its sites
Registry title
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Status
Recruiting
Phase
Phase 3
People taking part
142 people, planned
Started
29 Nov 2024
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Treatment taken
Record updated
24 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with myotonic dystrophy type 1 (DM1) who can still walk. It compares metformin with a placebo (dummy pill) for muscle function.

Age
18 to 70 years
Sex
Men and women
Disease stage
DM1 that still allows walking (a walking stick is allowed). MIRS score (a muscle weakness scale) of 3 or 4.
Biomarker or test result
DM1 confirmed by a genetic test.

Main reasons for not taking part

  • Pregnant or breast-feeding women, or men planning to conceive a child during the study
  • Allergy to metformin or its other ingredients
  • Tracheotomy, or breathing machine through a mask needed more than 12 hours per day or not breathing well enough with it
  • Creatinine clearance (a kidney test) below 50 ml/min
  • Serious heart problems, such as ejection fraction below 35%, certain heart rhythm or conduction problems without a pacemaker or defibrillator, or sustained ventricular tachycardia

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • DM1 disease confirmed by genetic analysis
  • Men and women between 18 and 70 years of age
  • Preserved walking abilities (stick assistance possible)
  • MIRS score 3 or 4
  • Women of childbearing potential under efficient contraception during treatment
  • Patient able to consent
  • All patients who have completed and signed the specific information and informed consent form
  • Affiliation to a social security system

Who cannot take part

  • Contraindications to Metformin (hypersensitivity to metformin or to one of the excipients)
  • Acute disease that may lead to tissue hypoxia
  • Creatinine clearance inferior to 50 ml/min
  • Cardiac:; Left ventricular ejection fraction below 35%; Conduction system disease on the electrocardiogram with PR interval >200 ms or QRS duration >110 ms without a pacemaker or an implantable defibrillator or cardiac electrophysiological study performed over the past 5 years; Third-degree or Second degree type II atrioventricular block without a pacemaker or an implantable defibrillator; Sustained ventricular tachycardia
  • Pregnant or breast-feeding women
  • Men with an intention to conceive a child during the time of the study
  • Respiratory:; Patient requiring tracheotomy or; Patient requiring non-invasive-ventilation: - more than 12 hours per day; - insufficiently ventilated

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study team hypothesize that non-diabetic patients with Myotonic dystrophy type I (DM1) will improve their symptoms, especially their motor deficit which is the main feature of the disease, because of the splicing defect correction by metformin.

Read full original descriptionShow less

The primary objective of the study is to evaluate the efficacy of metformin vs placebo, on the improvement of muscle function in patients with DM1 compared to its placebo.

As the secondary objectives, the study aims:

* To evaluate the safety of metformin on patient with DM1. * To evaluate the efficacy of metformin vs placebo on:

1. The hand-grip strength; 2. The thumb-index pinch strength; 3. The locomotor function; 4. The respiratory function; 5. The cardiac function; 6. The quality of life; 7. The daily and social activity.

The 2 groups in the trial

  • Metformin armTreatment being tested

    Patients randomized in Metformin arm will take metformin orally.

    Treatment: Treatment taken

  • Placebo receiversPlacebo, for comparison

    Patients randomized in placebo arm will take placebo orally in the same procedure as metformin taken.

    Treatment: Treatment taken

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease). A Phase III, Prospective, Multicentre, Randomized, Double-blind Controlled Study
Plain-language title
Metformin compared with placebo for muscle function in myotonic dystrophy type 1Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05532813, who can take part
Record updated
24 November 2025